Engineered immune cells take on childhood cancers in early trial
NCT ID NCT06500819
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them in a lab to better recognize and attack cancer cells, and then infusing them back into the patient. The main goals are to see if the cells can be manufactured reliably and to find a safe dose, while also watching for any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B7-H3 chimeric antigen receptor T cells (CAR T cells)
- What this could lead to
- If successful, this could point toward a new treatment option for children and young adults with hard-to-treat solid tumors like neuroblastoma and sarcoma.
- What could go wrong
- This is an early phase 1 trial with only 41 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors, and there are risks of side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?